Field S B
Curr Top Radiat Res Q. 1976 Jan;11(1):1-86.
The treatment of cancer using fast neutrons was first attempted from 1938 to 1942, only a few years after the identification of the particle in 1932. The radiobiological information which was available at that time was both inadequate and contradictory, and provided no definite rationale for using neutrons in preference to X-rays. The doses given were often too high, causing many patients to suffer severe late reactions. As a result, further attempts to use fast neutrons in radiotherapy were abandoned for nearly 30 years. Interest in the use of fast neutrons was stimulated again by the elucidation of the oxygen effect and the discovery that it was less for neutrons than for X-rays. Thus tumours containing hypoxic cells would be less protected against neutrons. Also the reduced repair of sublethal damage with neutrons provided at least a partial explanation of the miscalculation of dose in the early trial. This was confirmed by means of a series of experiments on pig skin, from which it was also concluded that late damage was not more severe after neutrons, compared with X-rays for a given degree of early damage. A new clinical trial began in 1966, and the results so far are encouraging. In order to relate radiotherapy experience with X-rays to neutrons, it is necessary to measure the relative biological effectiveness (RBE) of neutrons. This has been done for skin of man, pig, mouse and rat. Because of the smaller recovery from sublethal damage after neutrons, the RBE increases as the dose per fraction decreases, but the relationship between RBE and dose per fraction is the same for all four species. Similar information, but only for rodents, has been obtained for a variety of other normal tissues with both cyclotron-produced and monoenergetic 14 or 15 meV neutrons. Experiments with animal tumours have indicated that there might be a wide variation in RBE from tumour to tumour due both to the presence of hypoxic cells and to differences in their capacities to recover from sublethal damage after X-rays and neutrons. The largest series of experiments on one tumour shows that whereas certain fractionation techniques with X-rays may produce a poor tumour response for a given level of normal tissue damage, all the neutron regimes produced a similar, close to optimum result. There is no evidence from which to expect any special dangers from neutron irradiation, and their likely advantage is that they may provide a more reliable method of radiotherapy as well as sterilizing some tumours which are normally resistant to X-rays.
利用快中子治疗癌症最早是在1938年至1942年期间尝试的,此时距离1932年发现这种粒子仅过去了几年。当时可获得的放射生物学信息既不充分又相互矛盾,没有提供明确的理由说明为何优先使用中子而非X射线。所给予的剂量常常过高,导致许多患者遭受严重的晚期反应。结果,在放射治疗中使用快中子的进一步尝试被搁置了近30年。对氧效应的阐明以及发现中子的氧效应比X射线小,这再次激发了人们对使用快中子的兴趣。因此,含有乏氧细胞的肿瘤对中子的防护作用较小。此外,中子对亚致死性损伤的修复减少,这至少部分解释了早期试验中剂量计算的错误。通过对猪皮肤进行的一系列实验证实了这一点,从这些实验中还得出结论,在给定程度的早期损伤情况下,与X射线相比,中子照射后的晚期损伤并不更严重。1966年开始了一项新的临床试验,到目前为止结果令人鼓舞。为了将X射线放疗经验与中子放疗经验联系起来,有必要测量中子的相对生物效应(RBE)。已经对人、猪、小鼠和大鼠的皮肤进行了测量。由于中子照射后亚致死性损伤的恢复较小,随着分次剂量的降低,RBE会增加,但对于所有这四个物种,RBE与分次剂量之间的关系是相同的。对于多种其他正常组织,使用回旋加速器产生的和单能的14或15兆电子伏中子,也获得了类似的信息,但仅针对啮齿动物。对动物肿瘤的实验表明,由于乏氧细胞的存在以及不同肿瘤在接受X射线和中子照射后从亚致死性损伤中恢复能力的差异,不同肿瘤之间的RBE可能存在很大差异。对一种肿瘤进行的最大规模系列实验表明,对于给定水平的正常组织损伤,某些X射线分次照射技术可能导致较差的肿瘤反应,而所有中子照射方案都产生了相似的、接近最佳的结果。没有证据表明中子照射会带来任何特殊危险,而且它们可能的优势在于,它们可能提供一种更可靠的放射治疗方法,还能使一些通常对X射线有抗性的肿瘤失活。